SCHEMBL18263282

SCHEMBL18263282

CCC[C@@H](CCl)CC(=O)N[C@@H](CC)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOD1 Q9Y239 5/20 0.39
HDAC2 Q92769 2/20 0.37
MME P08473 3/20 0.36
CHRM1 P11229 1/20 0.34
AKR1A1 P14550 1/20 0.34
CHRM3 P20309 1/20 0.34
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34
ADRA1A P35348 1/20 0.34
HRH1 P35367 1/20 0.34
DRD3 P35462 1/20 0.34
SLC6A3 Q01959 1/20 0.34
HDAC1 Q13547 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
POLB P06746 2/20 0.33
FPR2 P25090 1/20 0.33
CA2 P00918 1/20 0.33
CA4 P22748 1/20 0.33
SLC6A5 Q9Y345 1/20 0.32
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20212363 1.00 NOD1 (0.39) NOD1HDAC2MMECHRM1AKR1A1
SCHEMBL18263302 0.86 NOD1 (0.34) NOD1HDAC2CA2
SCHEMBL18263300 0.86 NOD1 (0.34) NOD1HDAC2CA2
SCHEMBL21014407 0.86 NOD1 (0.34) NOD1HDAC2CA2
SCHEMBL31299922 0.86 NOD1 (0.34) NOD1HDAC2CA2
SCHEMBL18271806 0.84 HDAC2 (0.39) HDAC2MMEPOLBCA2
SCHEMBL21014800 0.84 BMP1 (0.34)
SCHEMBL31444803 0.81 MME (0.43) NOD1HDAC2MMEPOLBCA2
SCHEMBL20232398 0.77 CA2 (0.41) NOD1HDAC2TDP1CA2SLC6A5
SCHEMBL10609081 0.74 HDAC2 (0.40) NOD1HDAC2MMECHRM1AKR1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199541-A9 PROCESSES TO PRODUCE BRIVARACETAM SUZHOU PENGXU PHARMATECH CO. LTD. (CN) 2024-06-20 US disclosed
EP-3302441-B1 PROCESSES TO PRODUCE BRIVARACETAM SUZHOU PENGXU PHARMATECH CO LTD (CN) 2023-12-13 EP disclosed
US-11673862-B2 Processes to produce brivaracetam SUZHOU PENGXU PHARMATECH CO. LTD. (CN) 2023-06-13 US disclosed
US-20190152908-A1 PROCESSES TO PRODUCE BRIVARACETAM ESTEVE QUIMlCA S.A. (ES) 2019-05-23 US disclosed
US-20190152909-A1 PROCESSES TO PRODUCE BRIVARACETAM ESTEVE QUIMlCA S.A. (ES) 2019-05-23 US disclosed
US-10221134-B2 Processes to produce brivaracetam ESTEVE QUIMICA S.A. (ES) 2019-03-05 US disclosed
US-20180155284-A1 PROCESSES TO PRODUCE BRIVARACETAM ESTEVE QUIMlCA S.A. (ES) 2018-06-07 US disclosed
EP-3302441-A1 PROCESSES TO PRODUCE BRIVARACETAM Suzhou Pengxu Pharmatech Co., Ltd. (CN) 2018-04-11 EP disclosed
WO-2016191435-A1 PROCESSES TO PRODUCE BRIVARACETAM WANG PENG (US) 2016-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11673862-B2 Processes to produce brivaracetam BLVRB, CYP3A4, POR NOD1 2652/4885HDAC2 1186/4885MME 3613/4885
US-20190152908-A1 PROCESSES TO PRODUCE BRIVARACETAM BLVRB, CYP3A4, POR NOD1 2652/4885HDAC2 1186/4885MME 3613/4885
US-10221134-B2 Processes to produce brivaracetam BLVRB, CYP3A4, POR NOD1 2652/4885HDAC2 1186/4885MME 3613/4885
US-20190152909-A1 PROCESSES TO PRODUCE BRIVARACETAM BLVRB, CYP3A4, POR NOD1 2652/4885HDAC2 1186/4885MME 3613/4885
US-20240199541-A9 PROCESSES TO PRODUCE BRIVARACETAM BLVRB, CYP3A4, POR NOD1 2652/4885HDAC2 1186/4885MME 3613/4885
US-20180155284-A1 PROCESSES TO PRODUCE BRIVARACETAM BLVRB, CYP3A4, POR NOD1 2652/4885HDAC2 1186/4885MME 3613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.